Blog - Page 2439 of 5623

TuesdayDec 06, 2016 4:51 pm

National Waste Management Holdings, Inc. (NWMH) Protects the Environment with a Range of Green Services

In the ‘Advancing Sustainable Materials Management: 2014 Fact Sheet’ (http://dtn.fm/JH1hf) published last month, the U.S. Environmental Protection Agency (EPA) released statistics on the amount of municipal solid waste (MSW) and construction and demolition (C&D) debris generated by U.S. households and businesses. The rising amounts pose a growing risk to the environment and to our health. The range of materials requiring disposal is also increasing. Since the dawn of the electronic and digital ages, varieties of electronic waste (e-waste), which include computers and associated devices and materials, have multiplied. This mountain of waste poses a troubling challenge to the health of…

TuesdayDec 06, 2016 2:52 pm

Animal Spirits at OurPet’s Company (OPCO) are Propelling Performance

The management at OurPet’s Company (OTCQX: OPCO) is driven by animal spirits. They’ve taken the quite mundane business of pet care and turned it into a high tech, high touch enterprise. Products now range from the groundbreaking OurPets® Big Dog Feeder® (http://dtn.fm/hG4WS) to the Intelligent Pet Care™ line (http://dtn.fm/dK3Al), which uses digital technologies to enhance communication with pets. In an industry that is growing twice as fast as the economy, OurPet’s Company is racing ahead at double the industry pace. In its third quarter 10-K, published November 14, 2016, the company shows that this pace has not lessened. Revenues for…

TuesdayDec 06, 2016 1:35 pm

Cellceutix Corp. (CTIX) Advances Pipeline toward Multi-billion Dollar Opportunities, Piques Peer Interest along the Way

Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several key markets. Advancements of its current pipeline – spanning dermatology, cancer, infectious disease and gastrointestinal indications – also set the company on course to achieve another season of remarkable progress. Cellceutix’s lead cancer drug candidate is Kevetrin™, an Orphan Drug anti-cancer agent entering phase 2a clinical trials for the treatment of ovarian cancer. Upon commercialization, Kevetrin would be the world’s…

TuesdayDec 06, 2016 11:55 am

Singlepoint, Inc. (SING) Offers Update on Corporate Initiatives Related to SingleSeed Subsidiary

Before the opening bell, Singlepoint, Inc. (OTC: SING) issued an update on the corporate initiatives being taken by its SingleSeed subsidiary in order to better position itself in the growing domestic cannabis industry. Following November’s vote, more than half of all U.S. states have now legalized marijuana for either recreational or medicinal purposes, leading to a figurative ‘green rush’ comprised of businesses seeking to capitalize on the emergence of the industry. SingleSeed, in particular, is focused on providing improved access to electronic payment options for dispensaries and similar businesses. Although banking is currently highly restricted based on federal regulations regarding…

TuesdayDec 06, 2016 10:12 am

Heron Therapeutics (HRTX) Helps Chemo Patients Prevent Vomiting with SUSTOL®

Cancer is the great scourge of our age. This year, 1.7 million Americans will find out they have the disease and some 600,000 will die from it. In total, approximately 40 percent of the population can expect to be diagnosed with cancer during their lifetime. The name “cancer” is derived from the Greek word for crab and may have been bestowed to indicate the tenacity of the disorder. Cancer tends to persist with the same relentlessness as the claws of a crab cling to a victim. Yet despite its stubbornness, cancer treatments like chemotherapy have reduced fatalities. Cancer is a…

MondayDec 05, 2016 5:58 pm

Neuralstem, Inc. (CUR) Gets Aegis Update

Neuralstem, Inc. (NASDAQ: CUR) is a biotechnology company whose patented technology allows for the production, on a commercial level, of a number of types of central nervous stem cells. These are in the development stage for the treatment of conditions and diseases of the central nervous system. The company recently announced the start of enrollment of patients for its phase II trial of NSI-189, a drug developed after Neuralstem did research into neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of neurons. On November 7 of this year, Aegis…

MondayDec 05, 2016 1:24 pm

Singlepoint (SING) Subsidiary Looks to Help Cannabis Merchants Build Trust, Increase Customer Loyalty

A leading provider of mobile technology and mobile payment solutions serving various markets and industries, Singlepoint, Inc. (OTC: SING) has its eyes set on the fast-growing cannabis industry, aiming to help legal marijuana businesses build trust and increase customer loyalty via subsidiary SingleSeed and its highly reliable payment processing and marketing tools. With eight more states voting to legalize either medical or recreational marijuana use last month, the marijuana industry is set to exceed $7 billion this year and to reach roughly $20 billion by 2020. However, legal businesses operating in the sector still find it hard to obtain support…

MondayDec 05, 2016 10:13 am

European Patent Dispute Spurs Buying Opportunity with Higher Price Target for Alder Biopharmaceuticals (ALDR)

A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), according to an analysis report (http://dtn.fm/9UkRd) released by Aegis Capital Corp on November 23. As such, Aegis analysts reiterated a ‘Buy’ rating for the company and proposed a higher stock price target of $41, compared to the $25.28 stock price at the time the report was issued. The report acknowledges that the ruling by the European Patent Office’s Opposition Division is unfavorable to product candidate ALD403 and…

FridayDec 02, 2016 4:37 pm

Singlepoint, Inc. (SING) CEO Discusses Influx of Calls from Cannabis Dispensaries on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future. To view this week’s program, visit www.MoneyTV.net In the interview, Greg Lambrecht, chief executive officer of Singlepoint, offered prospective investors an update on the progress of the company’s SingleSeed subsidiary, which it awakened from a quiet period in early November in an effort…

FridayDec 02, 2016 2:06 pm

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two in clinical stage one trials (M281 and M923), one in the process of being BLA and NDA accepted (40 mg/ml COPAXONE®), and two already being sold at market (LOVENOX® and 20 mg/ml COPAXONE®). Most recently, the company announced positive top-line phase III results for M923,…

Site Search

Company Search